Kyverna Therapeutics

KYTXPhase 3

Emeryville, United StatesFounded 2018kyvernatx.com

Kyverna Therapeutics is advancing a new class of cellular therapies designed to reset the immune system in patients with severe autoimmune diseases. The company leverages its proprietary synthetic biology platform to engineer CD19-targeting CAR T-cells, with its lead asset KYV-101 showing promising early clinical data. Following a successful IPO in February 2024, Kyverna is rapidly advancing multiple clinical programs while expanding its pipeline into additional autoimmune indications. The company represents a pioneering force in applying cell therapy beyond oncology to address significant unmet needs in autoimmunity.

Market Cap

$473.3M

Founded

2018

Employees

100-200

Focus

Biotech

KYTX · Stock Price

USD 7.9422.16 (-73.62%)

Historical price data

AI Company Overview

Technology Platform

Proprietary CD19-targeting CAR T-cell platform with fully human CAR construct and fractionated dosing regimen designed specifically for autoimmune disease applications.

Pipeline Snapshot

12 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101	Myasthenia Gravis	Phase 2/3
Standard lymphodepletion regimen	Stiff-Person Syndrome	Phase 2
KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mAB	Multiple Sclerosis, Primary Progressive	Phase 2
KYV-101 + Standard lymphodepletion regimen	Systemic Sclerosis	Phase 1/2
KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodepletion regimen	Lupus Nephritis	Phase 1/2

Funding History

Total raised: $404M

IPO$319MUndisclosedFeb 8, 2024

Series B$85MGilead SciencesJan 15, 2023

Opportunities

Kyverna has the opportunity to establish a new treatment paradigm for autoimmune diseases, moving from chronic management to potential cures.

The platform could expand to address dozens of autoimmune conditions affecting millions of patients globally.

Successful clinical validation could lead to premium pricing and significant market share in multi-billion dollar autoimmune markets.

Risk Factors

Key risks include clinical trial failures, safety issues with CAR T therapy in autoimmune patients, manufacturing complexities, intense competition from other cell therapy companies, and reimbursement challenges for high-priced one-time therapies.

The novel mechanism in autoimmunity carries significant regulatory and biological uncertainty.

Competitive Landscape

Kyverna faces competition from other autoimmune CAR T developers like Cabaletta Bio and Cartesian Therapeutics, as well as established biologic therapies from large pharma. Differentiation comes from clinical advancement, proprietary dosing regimen, and a broad pipeline targeting multiple autoimmune indications simultaneously.

Publications

Patents

Pipeline